Ocular Therapeutix, Inc.

OTX-TIC(travoprost intracameral implant)

DESIGNED TO ADDRESS THE ISSUE OF PATIENT NON-COMPLIANCE WITH EYE DROPS

In preclinical and early clinical trials, OTX-TIC exhibited an acceptable safety profile, maintenance of drug levels in the aqueous humor, and a sustained lowering of intraocular pressure.¹

EXISTING TREATMENTS

High rates of non-adherence to glaucoma therapies^2-4

Poor adherence has been shown to be associated with disease progression and vision loss^5,6

Ocular hyperemia⁷

Life-long daily burden of patient administration⁸

PRODUCT CANDIDATE ATTRIBUTES

Travoprost-loaded microparticles embedded in hydrogel¹

Administered with 27G or 26G needle⁹

Resides in the iridocorneal angle¹

Fully biodegradable¹